LAS 191351Alternative Names: LAS191351
Latest Information Update: 09 Sep 2016
Price : $50
At a glance
- Originator Almirall S.A.
- Class Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 27 Apr 2016 Phase-I clinical trials in Chronic obstructive pulmonary disease in Spain (Inhalation) (Almirall pipeline, April 2016)